VYGR
Voyager Therapeutics, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $6.47 | $38 | +493% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $6.47 | $38 | +493% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $6.47 | $38 | +493% |
| Millennium Management re-entered | Q4 2024(8Q snapshot) | 6Q | $6.22 | $38 | +517% |
| Point72 Asset Management re-entered | Q1 2025(8Q snapshot) | 5Q | $4.23 | $38 | +807% |
| Two Sigma Investments re-entered | Q4 2025(8Q snapshot) | 2Q | $20 | $38 | +93% |
| Soros Fund Management | Q1 2026(8Q snapshot) | 1Q | $26 | $38 | +47% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Renaissance Technologies 2× in & out | Q4 2025 | Q1 2026 | → $26 | +22% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Voyager Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001104659-26-039691Apr 3, 2026
- Form 40001104659-26-039689Apr 3, 2026
- Form 40001104659-26-020183Feb 26, 2026
- Form 40001104659-26-020181Feb 26, 2026
- Form 40001104659-26-020179Feb 26, 2026
- Form 40001104659-26-020176Feb 26, 2026
- Form 40001104659-26-018131Feb 20, 2026
- Form 40001104659-26-018130Feb 20, 2026
- Form 40001104659-26-018126Feb 20, 2026
- Form 40001104659-26-013416Feb 11, 2026
- Form 40001104659-26-013414Feb 11, 2026
- Form 40001104659-26-013408Feb 11, 2026
- Form 40001104659-26-012679Feb 10, 2026
- Form 40001104659-26-012677Feb 10, 2026
- Form 40001104659-26-012675Feb 10, 2026
Fundamentals
XBRL · Voyager Therapeutics, Inc.Annual figures sourced directly from Voyager Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Voyager Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KJun 1, 2026
- 8-KMaterial eventMay 7, 2026
- 10-QQuarterly reportMay 7, 2026
- DEF 14AProxy statementApr 28, 2026
- 8-KFORM 8-KApr 21, 2026
- 8-KMaterial eventMar 9, 2026
- 10-KAnnual reportMar 9, 2026
- 8-KFORM 8-KFeb 12, 2026
- 8-KFORM 8-KJan 8, 2026
- S-3Registration (shelf)Nov 10, 2025
- 10-QQuarterly reportNov 10, 2025
- 8-KMaterial eventNov 10, 2025
- 8-KFORM 8-KSep 2, 2025
- 10-QQuarterly reportAug 6, 2025
- 8-KMaterial eventAug 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $3.77 | $3.53 | -6% |
| AQR Capital Management | Q2 2026 | open | $34 | $38 | +11% |
| Citadel Advisors | Q1 2026 | open | $27 | $38 | +44% |
| D.E. Shaw | Q1 2026 | open | $27 | $38 | +44% |
| Point72 Asset Management | Q1 2026 | open | $27 | $38 | +44% |
| Point72 Asset Management | Q1 2026 | open | $3.41 | $3.53 | +4% |
| Soros Fund Management | Q1 2026 | open | $26 | $38 | +47% |
| Two Sigma Investments | Q4 2025 | open | $20 | $38 | +93% |
| Two Sigma Investments | Q4 2025 | open | $3.93 | $3.53 | -10% |
| Renaissance Technologies | Q4 2025 | Q1 2026 | $21 | $26 | +22% |
| Citadel Advisors | Q3 2025 | Q4 2025 | $31 | $20 | -35% |
| Millennium Management | Q3 2025 | open | $31 | $38 | +25% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $4.23 | $3.28 | -22% |
| Millennium Management | Q4 2024 | open | $6.22 | $3.53 | -43% |
| Citadel Advisors | Q3 2024 | open | $6.47 | $3.53 | -45% |
| D.E. Shaw | Q3 2024 | Q1 2025 | $6.47 | $4.23 | -35% |
| AQR Capital Management | Q3 2024 | open | $6.47 | $3.53 | -45% |
| Renaissance Technologies | Q3 2024 | open | $6.92 | $3.53 | -49% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.